MX2015012424A - Prediccion de la respuesta a los inhibidores de egfr. - Google Patents

Prediccion de la respuesta a los inhibidores de egfr.

Info

Publication number
MX2015012424A
MX2015012424A MX2015012424A MX2015012424A MX2015012424A MX 2015012424 A MX2015012424 A MX 2015012424A MX 2015012424 A MX2015012424 A MX 2015012424A MX 2015012424 A MX2015012424 A MX 2015012424A MX 2015012424 A MX2015012424 A MX 2015012424A
Authority
MX
Mexico
Prior art keywords
egfr inhibitors
predicting response
methods
predicting
response
Prior art date
Application number
MX2015012424A
Other languages
English (en)
Inventor
Geraldine Strasser
Bryan Lo
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2015012424A publication Critical patent/MX2015012424A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se proporcionan métodos para predecir si un cáncer responderá a un inhibidor de EGFR.
MX2015012424A 2013-03-14 2014-03-12 Prediccion de la respuesta a los inhibidores de egfr. MX2015012424A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361781187P 2013-03-14 2013-03-14
PCT/US2014/024544 WO2014159638A1 (en) 2013-03-14 2014-03-12 Predicting response to egfr inhibitors

Publications (1)

Publication Number Publication Date
MX2015012424A true MX2015012424A (es) 2016-01-12

Family

ID=50733298

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012424A MX2015012424A (es) 2013-03-14 2014-03-12 Prediccion de la respuesta a los inhibidores de egfr.

Country Status (13)

Country Link
US (1) US20140314747A1 (es)
EP (1) EP2971108A1 (es)
JP (1) JP2016513969A (es)
KR (1) KR20150130422A (es)
CN (1) CN105074006A (es)
AU (1) AU2014244593A1 (es)
BR (1) BR112015022273A2 (es)
CA (1) CA2902913A1 (es)
HK (1) HK1211626A1 (es)
IL (1) IL240468A0 (es)
MX (1) MX2015012424A (es)
SG (1) SG11201507040VA (es)
WO (1) WO2014159638A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011009729A (es) * 2009-03-20 2011-10-14 Genentech Inc Anticuerpos anti-her.
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2592155B2 (en) * 2004-06-04 2019-09-11 Genentech, Inc. EGFR mutations
WO2010036928A1 (en) * 2008-09-26 2010-04-01 Takeda Pharmaceutical Company Limited Prevention and treatment of cancer with lkb1 non-expression (deletion or mutation)
EP2507392A4 (en) * 2009-11-30 2013-06-05 Merck Sharp & Dohme METHOD OF IDENTIFYING AND TREATING PATIENTS SENSITIVE TO ANTI-IGF-1R INHIBITION THERAPY

Also Published As

Publication number Publication date
JP2016513969A (ja) 2016-05-19
WO2014159638A1 (en) 2014-10-02
BR112015022273A2 (pt) 2017-10-10
KR20150130422A (ko) 2015-11-23
CN105074006A (zh) 2015-11-18
SG11201507040VA (en) 2015-10-29
CA2902913A1 (en) 2014-10-02
HK1211626A1 (en) 2016-05-27
US20140314747A1 (en) 2014-10-23
IL240468A0 (en) 2015-09-24
EP2971108A1 (en) 2016-01-20
AU2014244593A1 (en) 2015-08-27

Similar Documents

Publication Publication Date Title
EP3688157A4 (en) HIGH EFFICIENCY TARGETED PANGENOMIC IN-SITU PROFILING
EP2970218B8 (en) Dna-pk inhibitors
EP3120286A4 (en) Behavior profiling for malware detection
SG10201900574SA (en) Virtual currency conversion device, method and computer program
BR112017004334A2 (pt) inibidores de desmetilase específica de lisina-1.
GB201421088D0 (en) New enzyme inhibitors
EP3118801A4 (en) Purchase information utilization system, purchase information utilization method, and program
UY34654A (es) Inhibidores de la beta-secretasa
EP3095055A4 (en) Biopsy-driven genomic signature for prostate cancer prognosis
EP3026140A4 (en) Steel plate for line pipe, and line pipe
UY34666A (es) Inhibidores de quinasa a base de ariléter
EP3008210A4 (en) Methods for detecting prostate cancer
EP3017416A4 (en) Financial account authentication
EP3314508A4 (en) Profiling event based exploit detection
EP3176269A4 (en) Novel biomarker for predicting sensitivity to met inhibitor, and use thereof
EP3036712A4 (en) Methods for predicting prognosis
EP3146978A4 (en) Cancer stem cell proliferation inhibitor
BR112014027219A2 (pt) método
HK1223746A1 (zh) 放大級工作點的確定
MX2015009680A (es) Metodos y sistemas para recuperacion de agua.
EP3148971A4 (en) Deubiquitinase inhibitors
EP3238469A4 (en) POWER SAVING TECHNIQUES FOR eMBMS
EP3068538A4 (en) Stepped shredder hammers
EP3126528A4 (en) Methods for determining responsiveness to mek/erk inhibitors
MY156871A (en) Detection methods for oil palm shell alleles